Text Size

Study to Compare Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) in Glaucoma Patients (TRASCO)

This study is currently recruiting participants.
Verified May 2009 by University Hospital Tuebingen
Sponsor:
Collaborator:
Alcon Research
Information provided by:
University Hospital Tuebingen
ClinicalTrials.gov Identifier:
NCT00902109
First received: May 12, 2009
Last updated: February 11, 2011
Last verified: May 2009
History of Changes
  Purpose

The purpose of this study is to compare the two psychophysical perimetric techniques regarding progression of the visual field.


Condition Intervention
Primary Open Angle Glaucoma
 Other: Perimetry
Other: SCOPE + GATE
Procedure: Scotoma-oriented perimetry

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Pilot Study to Compare the HFA 30-2 SITA Standard Perimetry With the New Scotoma-Oriented Perimetry (SCOPE), Using a New Fast GATE (German Adaptive Threshold Estimation) in Glaucoma Patients Under Topic Beta Blocker Monotherapy

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by University Hospital Tuebingen:

Estimated Enrollment: 12
Study Start Date: April 2010
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
open angle glaucoma
open angle glaucoma, treated with topic therapy
 Other: Perimetry
different perimetric grids
Other Name: Humphrey, Octopus
Other: SCOPE + GATE
New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation
Other Name: Humphrey, Octopus
Procedure: Scotoma-oriented perimetry
perimetry
Other Name: Humphrey, Octopus

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

University Eye Hospital

Criteria

Inclusion Criteria:

  • primary open angle glaucoma (POAG)
  • betablocker therapy
  • spherical ametropia max. ± 8 dpt
  • cylindrical ametropia max. ± 3 dpt
  • distant visual acuity > 10/20
  • pupil diameter > 3 mm

Exclusion Criteria:

  • diabetic retinopathy
  • asthma
  • history of epilepsy or significant psychiatric disease
  • medications known to effect visual field sensitivity
  • infections (e.g., keratitis, conjunctivitis, uveitis)
  • severe dry eyes
  • miotic drug
  • squint
  • nystagmus
  • albinism
  • any ocular pathology, in either eye, that may interfere with the ability to obtain visual fields
  • keratoconus
  • intraocular surgery (except for uncomplicated cataract surgery) performed < 3 month prior to screening
  • history or signs of any visual pathway affection other than glaucoma
  • history or presence of macular disease and/or macular edema, ocular trauma, medications known to affect visual field sensitivity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00902109

Contacts
Contact: Ulrich Schiefer, MD ++49 7071 29 ext 84786 ulrich.schiefer@med.uni-tuebingen.de

Locations
Germany
Institute for Ophthalmic Research Recruiting
Tuebingen, Germany, 72076
Contact: Elke Krapp     ++49 7071 29 ext 8 07 26     elke.krapp@med.uni-tuebingen.de    
Principal Investigator: Ulrich Schiefer, MD            
Sponsors and Collaborators
University Hospital Tuebingen
Alcon Research
  More Information

Publications:

Responsible Party: Prof. Dr. med. Ulrich Schiefer, Centre for Ophthalmology, Institute for Ophthalmic Research
ClinicalTrials.gov Identifier: NCT00902109     History of Changes
Other Study ID Numbers: SCOPE-G-BETA
Study First Received: May 12, 2009
Last Updated: February 11, 2011
Health Authority: Germany: Ethics Commission

Keywords provided by University Hospital Tuebingen:
visual field
perimetry
progression
POAG with topic beta blocker monotherapy

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Ocular Hypertension
Eye Diseases
Adrenergic beta-Antagonists
Adrenergic Antagonists
 Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 21, 2013